Loading
Life sciences · Journal article
Frontiers in Immunology · October 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Pancreatic ductal adenocarcinoma (PDAC) develops within a dense, poorly perfused tumor microenvironment (TME) in which cancer-associated fibroblasts (CAFs) are prominent cellular and structural components. Once viewed as a uniform population of activated matrix-producing cells, CAFs now include myofibroblastic, inflammatory, antigen-presenting and other populations identified by single-cell and spatial studies. These categories sharpen experimental resolution but do not form a stable hierarchy. CAF phenotypes overlap across spatial niches and disease stages, and they change under metabolic stress or treatment. We frame this heterogeneity as a set of context-dependent functional states. This review synthesizes evidence on fibroblast origins, canonical and recently reported states, and the signals that drive state transitions. It then examines CAF functions in extracellular matrix organization, tumor-cell plasticity and dissemination, metabolic support and immune regulation. Findings on tumor-restraining fibroblasts and protective collagen pools challenge indiscriminate stromal depletion. We also assess CAF states as prognostic and predictive biomarkers, their roles in treatment resistance and therapeutic strategies based on depletion, pathway blockade or stromal normalization. Failures of Hedgehog and hyaluronan-directed therapies show that target abundance alone cannot select patients. Clinical translation will require state definitions that integrate function, spatial context and treatment history, supported by reproducible markers, prospective validation and models that retain human stromal diversity.